Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GSK 3943104A

Next Previous
Drug Profile

GSK 3943104A

Alternative Names: GSK-3943104; GSK-3943104A

Latest Information Update: 12 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GSK
  • Class Protein vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Herpes simplex virus infections

Most Recent Events

  • 12 Jun 2025 GlaxoSmithKline completes the Phase-I/II clinical trials in Herpes simplex virus infections in USA, Canada, Belgium, Estonia, Spain, Germany, Australia (IM) (NCT05298254)
  • 06 Feb 2024 Phase-II clinical trials in Herpes simplex virus infections (In adults, In the elderly) (Parenteral), prior to February 2024 (GlaxoSmithKline pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top